Option Sale OpportunityCRSP is admittedly a VERY volatile name, but one with a big future and I believe a CL list stock at GS.
On Friday, I was able to sell the May $45 puts for $1.90.
If I am exercised, my cost basis will be $43.10, which puts it right in the support of the bottom of the last pullback.
I would be OK getting exercised on that and I could exit for a small loss if it violated the low of that prior pullback.
If I don't get exercised, I've earned roughly 4% of the strike price for 4 weeks exposure for a strike that is roughly 20% OTM.
I can live with that, too, as one will come close to making my monthly car payment.
Drawback: There is obviously an earnings report between now and expiration.
Add your thoughts
1CG trade ideas
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com
NASDAQ:CRSP
Many Thanks.
R.M.D
Investing In GenomicsAnyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com
NASDAQ:CRSP
Many Thanks.
R.M.D
CRSP In For A Positive YearCRSP Gains, gains, more gains. Looking good so far this year. Gene editing seeking to cure diseases and cancer. Don't sleep on this one. Hitting some all time highs right now so wait for a moment to get down to the $22's and $21's and watch for a good return in the future.